Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Impact Of Higher Part D Donut Hole Discounts Beginning To Show: Xarelto Sales Down 19%

Performance of Johnson & Johnson’s blockbuster cardiovascular drug is one of the first prominent examples of how the 2019 increase in the discount from 50% to 70% is playing out in the market.

Reimbursement Medicare

Insulin Application Reviews Would Continue After March 2020 Under Senate Bill

Bill would change US FDA's approach to handling follow-on applications submitted under Section 505 once products become "deemed" as biologics 23 March 2020, and could amend a provision in the Senate HELP Committee's health care bill, which aligns with FDA policy.

Biosimilars Biologics

International Price Index Will Advance Under New CMMI Chief – If It’s Implemented

Adam Boehler will leave HHS and his post as director of the Center for Medicare and Medicaid Innovation to move to another job in the Administration.

Pricing Debate Reimbursement

A Case For List Price Cuts? Study Highlights Reduced 340B Liability For Hep C Drugs

Lower list prices for Epclusa, Harvoni, and Zepatier might actually boost revenue by reducing 340B discounts, but rebate-eschewing dynamic may not expand beyond them because of different exposures to 340B in other classes – and the pending HHS rebate rule.

Pricing Debate Reimbursement

White House Exec Order Will Bring US Parity With Lowest Drug Prices Abroad, Trump Says

Remarks to reporters prompt surprise and confusion among stakeholders and likely reflect the president’s impatience with the pace of regulatory and legislative pricing reforms.

Pricing Debate Regulation

As Washington Waits On Pricing Proposals, A Call For A Reset In R&D Debate

Policymakers should clarify link between high drug prices and innovation and figure out how to “rebalance” high prices with non-price innovation incentives before proceeding with policies aimed directly at lowering prices, Conti and David propose in the Health Affairs Blog.

Pricing Debate Reimbursement
See All
Advertisement
UsernamePublicRestriction

Register